Sheila Denton Takes the Helm as General Counsel at MiniMed, Aiming for Growth and Innovation

MiniMed Welcomes Sheila Denton as General Counsel and Corporate Secretary

MiniMed, a prominent name in the world of diabetes technology, has announced the appointment of Sheila Denton as its new General Counsel and Corporate Secretary. With a wealth of experience spanning over 25 years in the pharmaceutical and biotechnology sectors, Denton's addition to the MiniMed team signals a pivotal moment for the company as it seeks to expand its impact globally.

A New Chapter for MiniMed

The announcement comes at a time when MiniMed is positioned to scale its operations as an independent public company. Que Dallara, the CEO of MiniMed, expressed enthusiasm about Denton joining the ranks, emphasizing her proven track record of navigating corporate governance, regulatory landscapes, and strategic transformations. Dallara noted, "Sheila brings deep board experience, strong regulatory and transactional judgment, and a proven ability to build and lead high-performing global teams." This is particularly critical as MiniMed prepares for future growth initiatives.

Sheila Denton's Impressive Background

Before joining MiniMed, Denton served as the General Counsel at Incyte, where she was pivotal in guiding the company through various strategic ventures and corporate governance matters. Her professional journey encompasses significant roles at Boehringer Ingelheim, where she held the title of US General Counsel and Corporate Head of Strategic Transactions, showcasing her diverse legal expertise across different jurisdictions. Her academic credentials include a Bachelor of Science from Sacred Heart University and a Juris Doctor degree from Western New England College School of Law.

Vision for the Future

Upon her appointment, Denton expressed eagerness about contributing to MiniMed’s mission. "I'm excited to join MiniMed at such an important moment in the company's journey," said Denton. She highlighted MiniMed's clear commitment to improving the daily lives of those with diabetes, stating, "I look forward to joining my MiniMed colleagues across the world as we build on the company's strong foundation and pursue the opportunities ahead." This vision aligns seamlessly with MiniMed's ongoing efforts to innovate within the diabetes management landscape.

A Leader in Diabetes Technology

MiniMed has long been a leader in the development and delivery of diabetes care solutions. The company's portfolio includes insulin delivery systems, continuous glucose monitors (CGMs), and other integrated technologies designed to improve patient outcomes. With Denton as a part of the leadership team, MiniMed aims to leverage her expertise to enhance its corporate governance and strategic initiatives, ultimately enabling more effective support for people living with diabetes.

Conclusion

As Denton steps into her new role, there is a shared anticipation within the company regarding the strides MiniMed will take under her legal guidance. As the company aims for innovation and expansion in the diabetes technology sector, Sheila Denton's leadership will undoubtedly play a crucial role in shaping the future of MiniMed.

The decision to appoint Denton comes on the heels of Courtney Nelson Wills' departure from the role, who has transitioned to new professional opportunities after providing transitional support. MiniMed's leadership is confident that Denton's unique skill set will advance the company through the complexities and challenges of the evolving healthcare landscape.

About MiniMed

Founded with the mission to make daily life better for individuals with diabetes, MiniMed continues to build on its 40-year legacy of innovation in diabetes management. The company's comprehensive ecosystem encompasses insulin delivery systems, cutting-edge algorithms, and user-friendly applications, all designed to integrate seamlessly and provide an enhanced healthcare experience. For more information, visit MiniMed's website.